The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IONS | +115.3% | +40.28% | +7% | +640% |
| S&P | +17.45% | +75.43% | +11.88% | +1,710% |
Ionis Pharmaceuticals is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $203.00M | -10.6% |
| Gross Profit | $191.10M | -12.2% |
| Gross Margin | 94.14% | -1.8% |
| Market Cap | $12.81B | 132.1% |
| Market Cap / Employee | $9.14M | 0.0% |
| Employees | 1.4K | 31.2% |
| Net Income | -$229,000.00K | -120.2% |
| EBITDA | -$207,659.00K | -98.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $372.26M | 53.8% |
| Accounts Receivable | $66.06M | -28.3% |
| Inventory | 10 | -19.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.16B | 10.9% |
| Short Term Debt | $453.15M | 4783.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.67% | 3.5% |
| Return On Invested Capital | -16.33% | -6.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$159,001.00K | -12.3% |
| Operating Free Cash Flow | -$137,709.00K | -18.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.10 | 13.21 | 16.49 | 20.63 | 147.69% |
| Price to Sales | 6.67 | 7.63 | 10.80 | 13.59 | 73.53% |
| Price to Tangible Book Value | 8.10 | 13.21 | 16.49 | 20.63 | 147.69% |
| Enterprise Value to EBITDA | -32.51 | 47.40 | -65.89 | -61.41 | 24.18% |
| Return on Equity | -118.5% | -59.8% | -40.0% | -70.7% | -23.98% |
| Total Debt | $1.96B | $1.97B | $2.05B | $2.61B | 33.47% |
The failed attempt to repeal and replace Obamacare last month has big implications for healthcare investors.
Merck, Gilead Sciences, and Ionis get a verdict in their patent suit, and Congress calls for a patent review of Medivation's Xtandi.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
